A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With Cipla Ltd..
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
150actual
Sites
12
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-18 | actual | When the study began enrolling |
| Primary completion | 2025-09-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-02 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: Insulin Lispro-aabc — also filed as LY900014
- Drug: Insulin Glargine
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with at least 1 Episode of Hypoglycemia
measured Baseline through Week 26
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed